Generic Drugs End-Payer Consumer Settlements (Sandoz and Sun/Taro)
The claim deadline for this settlement has passed.
- Claim deadline
- — check the official site for the exact cut-off time and postmark rules
- Who qualifies
- Consumers who paid some or all of the price of certain named generic drugs, other than for resale, between May 1, 2009 and December 31, 2019 in any U.S. state except Indiana and Ohio, or in the District of Columbia, Puerto Rico or the U.S. Virgin Islands. Consumers covered by Medicaid for their purchases are excluded. Indiana and Ohio purchases are not covered.
- Payout (as stated by the official source)
- Share of the $275 million Sandoz and $200 million Sun/Taro settlements, which also pay third-party payers such as insurers (amount varies)
- Proof of purchase / documentation
- Required. For each drug claimed, a receipt, account statement, pharmacy record or similar document showing at least one purchase between May 1, 2009 and December 31, 2019
- Defendant
- Sandoz Inc. and Fougera Pharmaceuticals Inc.; Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A., Inc.
- Case
- In re Generic Pharmaceuticals Antitrust Litigation, Case No. 16-MD-2724
U.S. District Court, Eastern District of Pennsylvania - Category
- Fees & pricing
Go to the official settlement website (genericdrugsendpayersettlement.com)
This link goes to the settlement administrator's website. Settlement Deadlines does not process claims and is not affiliated with the administrator.
Sources
- https://www.genericdrugsendpayersettlement.com/
- https://www.genericdrugsendpayersettlement.com/sandoz-classes-homepage
- https://www.genericdrugsendpayersettlement.com/sun-taro-classes-homepage
- https://www.genericdrugsendpayersettlement.com/assets/Docs/2026/EPP%20Consumer%20Claim%20Form.pdf
Last verified: . Claim deadline, settlement amounts and case details checked against the official settlement website and its consumer claim form on 2026-11-03. This private end-payer class action is separate from the state attorneys general generic-drug settlements. Details can change; the official website is authoritative.